Ahmed M. Alaa

Ahmed M. Alaa

Auto-generated profile, based on publicly available information

Ahmed M. Alaa

University of California, Berkeley; University of California, San Francisco

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAhmed M. Alaa
Ahmed M. Alaa
TBThomas Bolton
Thomas Bolton
EAEmanuele Di Angelantonio
Emanuele Di Angelantonio
JRJames H. F. Rudd
James H. F. Rudd
MSMihaela van der Schaar
Mihaela van der Schaar
Identifying people at risk of cardiovascular diseases (CVD) is a cornerstone of preventative cardiology. Risk prediction models currently recommended by clinical guidelines are typically based on a limited number of predictors with sub-optimal performance across all patient groups. Data-driven techniques based on machine learning (ML) might improve the performance of risk predictions by agnostically discovering novel risk predictors and learning the complex interactions between them. We tested (1) whether ML techniques based on a state-of-the-art automated ML framework (AutoPrognosis) could improve CVD risk prediction compared to traditional approaches, and (2) whether considering non-traditional variables could increase the accuracy of CVD risk predictions. Using data on 423,604 participants without CVD at baseline in UK Biobank, we developed a ML-based model for predicting CVD risk based on 473 available variables. Our ML-based model was derived using AutoPrognosis, an algorithmic tool that automatically selects and tunes ensembles of ML modeling pipelines (comprising data imputation, feature processing, classification and calibration algorithms). We compared our model with a well-established risk prediction algorithm based on conventional CVD risk factors (Framingham score), a Cox proportional hazards (PH) model based on familiar risk factors (i.e, age, gender, smoking status, systolic blood pressure, history of diabetes, reception of treatments for hypertension and body mass index), and a Cox PH model based on all of the 473 available variables. Predictive performances were assessed using area under the receiver operating characteristic curve (AUC-ROC). Overall, our AutoPrognosis model improved risk prediction (AUC-ROC: 0.774, 95% CI: 0.768-0.780) compared to Framingham score (AUC-ROC: 0.724, 95% CI: 0.720-0.728, p < 0.001), Cox PH model with conventional risk factors (AUC-ROC: 0.734, 95% CI: 0.729-0.739, p < 0.001), and Cox PH model with all UK Biobank variables (AUC-ROC: 0.758, 95% CI: 0.753-0.763, p < 0.001). Out of 4,801 CVD cases recorded within 5 years of baseline, AutoPrognosis was able to correctly predict 368 more cases compared to the Framingham score. Our AutoPrognosis model included predictors that are not usually considered in existing risk prediction models, such as the individuals’ usual walking pace and their self-reported overall health rating. Furthermore, our model improved risk prediction in potentially relevant sub-populations, such as in individuals with history of diabetes. We also highlight the relative benefits accrued from including more information into a predictive model (information gain) as compared to the benefits of using more complex models (modeling gain). Our AutoPrognosis model improves the accuracy of CVD risk prediction in the UK Biobank population. This approach performs well in traditionally poorly served patient subgroups. Additionally, AutoPrognosis uncovered novel predictors for CVD disease that may now be tested in prospective studies. We found that the “information gain” achieved by considering more risk factors in the predictive model was significantly higher than the “modeling gain” achieved by adopting complex predictive models.

3 April 2024 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
NMNikita Mehandru
Nikita Mehandru
BMBrenda Y. Miao
Brenda Y. Miao
EAEduardo Rodriguez Almaraz
Eduardo Rodriguez Almaraz
MSMadhumita Sushil
Madhumita Sushil
ABAtul J Butte
Atul J Butte
AAAhmed Alaa
Ahmed Alaa
Recent developments in large language models (LLMs) have unlocked opportunities for healthcare, from information synthesis to clinical decision support. These LLMs are not just capable of modeling language, but can also act as intelligent “agents” that interact with stakeholders in open-ended conversations and even influence clinical decision-making. Rather than relying on benchmarks that measure a model’s ability to process clinical data or answer standardized test questions, LLM agents can be modeled in high-fidelity simulations of clinical settings and should be assessed for their impact on clinical workflows. These evaluation frameworks, which we refer to as “Artificial Intelligence Structured Clinical Examinations” (“AI-SCE”), can draw from comparable technologies where machines operate with varying degrees of self-governance, such as self-driving cars, in dynamic environments with multiple stakeholders. Developing these robust, real-world clinical evaluations will be crucial towards deploying LLM agents in medical settings.

28 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJinsung Yoon
Jinsung Yoon
WZWilliam R Zame
William R Zame
ABAmitava Banerjee
Amitava Banerjee
MCMartin Cadeiras
Martin Cadeiras
AAAhmed M Alaa
Ahmed M Alaa
MSMihaela van der Schaar
Mihaela van der Schaar
Risk prediction is crucial in many areas of medical practice, such as cardiac transplantation, but existing clinical risk-scoring methods have suboptimal performance. We develop a novel risk prediction algorithm and test its performance on the database of all patients who were registered for cardiac transplantation in the United States during 1985-2015. We develop a new, interpretable, methodology (ToPs: Trees of Predictors) built on the principle that specific predictive (survival) models should be used for specific clusters within the patient population. ToPs discovers these specific clusters and the specific predictive model that performs best for each cluster. In comparison with existing clinical risk scoring methods and state-of-the-art machine learning methods, our method provides significant improvements in survival predictions, both post- and pre-cardiac transplantation. For instance: in terms of 3-month survival post-transplantation, our method achieves AUC of 0.660; the best clinical risk scoring method (RSS) achieves 0.587. In terms of 3-year survival/mortality predictions post-transplantation (in comparison to RSS), holding specificity at 80.0%, our algorithm correctly predicts survival for 2,442 (14.0%) more patients (of 17,441 who actually survived); holding sensitivity at 80.0%, our algorithm correctly predicts mortality for 694 (13.0%) more patients (of 5,339 who did not survive). ToPs achieves similar improvements for other time horizons and for predictions pre-transplantation. ToPs discovers the most relevant features (covariates), uses available features to best advantage, and can adapt to changes in clinical practice. We show that, in comparison with existing clinical risk-scoring methods and other machine learning methods, ToPs significantly improves survival predictions both post- and pre-cardiac transplantation. ToPs provides a more accurate, personalized approach to survival prediction that can benefit patients, clinicians, and policymakers in making clinical decisions and setting clinical policy. Because survival prediction is widely used in clinical decision-making across diseases and clinical specialties, the implications of our methods are far-reaching.

26 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AAAhmed M. Alaa
Ahmed M. Alaa
MSMihaela van der Schaar
Mihaela van der Schaar
Accurate prediction of survival for cystic fibrosis (CF) patients is instrumental in establishing the optimal timing for referring patients with terminal respiratory failure for lung transplantation (LT). Current practice considers referring patients for LT evaluation once the forced expiratory volume (FEV1) drops below 30% of its predicted nominal value. While FEV1 is indeed a strong predictor of CF-related mortality, we hypothesized that the survival behavior of CF patients exhibits a lot more heterogeneity. To this end, we developed an algorithmic framework, which we call AutoPrognosis, that leverages the power of machine learning to automate the process of constructing clinical prognostic models, and used it to build a prognostic model for CF using data from a contemporary cohort that involved 99% of the CF population in the UK. AutoPrognosis uses Bayesian optimization techniques to automate the process of configuring ensembles of machine learning pipelines, which involve imputation, feature processing, classification and calibration algorithms. Because it is automated, it can be used by clinical researchers to build prognostic models without the need for in-depth knowledge of machine learning. Our experiments revealed that the accuracy of the model learned by AutoPrognosis is superior to that of existing guidelines and other competing models.

27 April 2017 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
AAAhmed M. Alaa
Ahmed M. Alaa
JYJinsung Yoon
Jinsung Yoon
SHScott Hu
Scott Hu
MSMihaela van der Schaar
Mihaela van der Schaar
In this paper, we develop a personalized real-time risk scoring algorithm that provides timely and granular assessments for the clinical acuity of ward patients based on their (temporal) lab tests and vital signs; the proposed risk scoring system ensures timely intensive care unit (ICU) admissions for clinically deteriorating patients. Methods: The risk scoring system is based on the idea of sequential hypothesis testing under an uncertain time horizon. The system learns a set of latent patient subtypes from the offline electronic health record data, and trains a mixture of Gaussian Process (GP) experts, where each expert models the physiological data streams associated with a specific patient subtype. Transfer learning techniques are used to learn the relationship between a patient's latent subtype and her static admission information (e.g. age, gender, transfer status, ICD-9 codes, etc). Results: Experiments conducted on data from a heterogeneous cohort of 6,321 patients admitted to Ronald Reagan UCLA medical center show that our score significantly outperforms the currently deployed risk scores, such as the Rothman index, MEWS, APACHE and SOFA scores, in terms of timeliness, true positive rate (TPR), and positive predictive value (PPV). Conclusion: Our results reflect the importance of adopting the concepts of personalized medicine in critical care settings; significant accuracy and timeliness gains can be achieved by accounting for the patients' heterogeneity. Significance: The proposed risk scoring methodology can confer huge clinical and social benefits on a massive number of critically ill inpatients who exhibit adverse outcomes including, but not limited to, cardiac arrests, respiratory arrests, and septic shocks.

24 June 2021 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
AAAhmed M. Alaa
Ahmed M. Alaa
DGDeepti Gurdasani
Deepti Gurdasani
DFDavid Favara
David Favara
JRJem Rashbass
Jem Rashbass
MSMihaela van der Schaar
Mihaela van der Schaar